Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

913
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
913
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

364
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
364
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

633
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Critical Thinking Engagement and Assessment in Didactic Pharmacy Education: A Scoping Review.

American journal of pharmaceutical education·2026
Same author

The development of a cannabis risk assessment tool for patients with rheumatologic conditions: a Delphi study.

Clinical rheumatology·2025
Same author

Pharmacist-led screening for advanced fibrosis using the FIB-4 index in patients 65 years or older with a clinical suspicion for MASLD at a family medicine clinic.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Clinicopathological correlation of PTPN3 expression in breast cancer and in silico drug screening against PTPN3 for therapeutics.

Cancer genetics·2025
Same author

Reviving public provisioning in US health care.

Health affairs scholar·2025
Same author

Telemedicine virologic and immunologic outcomes in people living with HIV (PLWH) in a correctional setting during the SARS-CoV-2 pandemic.

BMC infectious diseases·2025

Related Experiment Video

Updated: Mar 21, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Establishing Edoxaban's Role in Anticoagulation.

Erenie Guirguis1, Dana Brown2, Yasmin Grace2

  • 1Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA erenie_guirguis@pba.edu.

Journal of Pharmacy Practice
|May 13, 2016
PubMed
Summary

Edoxaban is a new oral anticoagulant effective for preventing stroke in nonvalvular atrial fibrillation (AF) and treating venous thromboembolism (VTE). It offers advantages over warfarin but requires caution in patients with preserved renal function.

Keywords:
edoxabanoral anticoagulation

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Related Experiment Videos

Last Updated: Mar 21, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • Oral anticoagulants for stroke and venous thromboembolism (VTE) were historically limited to warfarin.
  • Newer oral anticoagulants (NOACs) offer benefits over warfarin.
  • Edoxaban is a novel, direct factor Xa inhibitor.

Purpose of the Study:

  • To review the literature on edoxaban for stroke prevention in nonvalvular atrial fibrillation (AF).
  • To review the literature on edoxaban for the treatment of venous thromboembolism (VTE).

Main Methods:

  • Review of current literature on edoxaban.
  • Analysis of clinical trial data regarding efficacy and safety.

Main Results:

  • Edoxaban is a safe and effective factor Xa inhibitor for patients with creatinine clearance <95 mL/min.
  • Edoxaban may offer advantages such as once-daily dosing and no cytochrome P450 (CYP450) interactions.
  • Concerns exist regarding higher stroke incidence in patients with AF and preserved renal function (>95 mL/min).

Conclusions:

  • Edoxaban provides an alternative oral anticoagulant option.
  • It is suitable for patients preferring once-daily dosing or those on medications interacting with CYP450.
  • Edoxaban demonstrates safety and efficacy in specific patient populations.